Download File - JOHN J. HADDAD, Ph.D.

Factoring in Antigen Processing in Designing Antitumor T-Cell Vaccines 27
101. Ayyoub M, Hesdorffer CS, Montes M, et al. An immunodominant SSX-2-derived
epitope recognized by CD4þ T cells in association with HLA-DR. J Clin Invest
2004; 113:1225–1233.
102. Valmori D, Levy F, Godefroy E, et al. Epitope clustering in regions undergoing
efficient proteasomal processing defines immunodominant CTL regions of a tumor
antigen. Clin Immunol 2007; 122:163–172.
103. van Hall T, Wolpert EZ, van Veelen P, et al. Selective cytotoxic T-lymphocyte
targeting of tumor immune escape variants. Nat Med 2006; 12:417–424.
104. Schirle M, Keilholz W, Weber B, et al. Identification of tumor-associated MHC
class I ligands by a novel T cell-independent approach. Eur J Immunol 2000;
30:2216–2225.
105. Alves P, Viatte S, Fagerberg T, et al. Immunogenicity of the carcinoembryonic
antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma
patients. Cancer Immunol Immunother 2007; 56:1795–1805.
106. Falo LD, Colarusso LJ, Benacerraf B, et al. Serum proteases alter the antigenicity of
peptides presented by class I major histocompatibility complex molecules. Proc
Natl Acad Sci USA 1992; 89:8347–8350.
107. Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic
class I peptides by human dendritic cells. J Immunol 1998; 161:4023–4032.
108. Bacik I, Cox JH, Anderson R, et al. TAP (transporter associated with antigen
processing)-independent presentation of endogenously synthesized peptides is
enhanced by endoplasmic reticulum insertion sequences located at the amino- but
not carboxyl-terminus of the peptide. J Immunol 1994; 152:381–387.
109. Martoglio B, Dobberstein B. Signal sequences: more than just greasy peptides.
Trends Cell Biol 1998; 8:410–415.
110. Finley D, Bartel B, Varshavsky A. The tails of ubiquitin precursors are ribosomal
proteins whose fusion to ubiquitin facilitates ribosome biogenesis. Nature 1989;
338:394–401.
111. Fruci D, Lauvau G, Saveanu L, et al. Quantifying recruitment of cytosolic peptides for
HLA class I presentation: impact of TAP transport. J Immunol 2003; 170:2977–2984.
112. Toes REM, Hoeben RC, van der Voort EIH, et al. Protective anti-tumor immunity
induced by vaccination with recombinant adenoviruses encoding multiple tumorassociated
cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl
Acad Sci USA 1997; 94:14660–14665.
113. Mateo L, Gardner J, Chen Q, et al. An HLA-A2 polyepitope vaccine for melanoma
immunotherapy. J Immunol 1999; 163:4058–4063.
114. Smith SG, Patel PM, Porte J, et al. Human dendritic cells genetically engineered to
express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell
responses. Clin Cancer Res 2001; 7:4253–4261.
115. Palmowski MJ, Choi EM-L, Hermans IF, et al. Competition between CTL narrows
the immune response induced by prime-boost vaccination protocols. J Immunol
2002; 168:4391–4398.
116. Tine JA, Firat H, Payne A, et al. Enhanced multiepitope-based vaccines elicit CD8 þ
cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine 2005;
23:1085–1091.
117. Slingluff CL Jr., Yamshchikov G, Neese P, et al. Phase I trial of a melanoma
vaccine with gp100280–288 peptide and tetanus helper peptide in adjuvant: immunologic
and clinical outcomes. Clin Cancer Res 2001; 7:3012–3024.